Role of adenosine antagonism in the cardio-renal syndrome: pathophysiology and therapeutic potential.
The adversarial relationship between the heart and the kidney in heart failure results from normal homeostatic mechanisms which become inappropriate in the setting of heart failure. The cardio-renal syndrome represents the sum total of this adversarial relation and is clinically manifest as worsening renal function limiting diuresis in spite of volume overload. Tubuloglomerular feedback is a major pathophysiologic component of this syndrome. Adenosine, acting via A1 receptors, plays a major role in tubuloglomerular feedback in the normal state and in cardio-renal syndrome. Preclinical studies and initial human studies suggest that adenosine antagonism increases diuresis and preserves glomerular filtration in the setting of decompensated heart failure. Considering the ubiquitous distribution of adenosine receptors in the body, it is crucial to tailor this therapeutic agent to avoid side effects, especially neurotoxicity. Larger studies are presently underway to understand the therapeutic potential of this novel class of agents.
Rajaram
Venkataraman
V
Cardiology Section (111), VA Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA 02132, USA.
Joseph
Jacob
J
D000241:Adenosine / Q000037:antagonists & inhibitors*; D058916:Adenosine A1 Receptor Antagonists; D000818:Animals; D004231:Diuresis / Q000187:drug effects; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D011379:Prognosis; D012079:Renal Circulation / Q000187:drug effects* / Q000502:physiology; D051437:Renal Insufficiency / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D058916:Adenosine A1 Receptor Antagonists; D014665:Vasodilator Agents; D000241:Adenosine